Navigation Links
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Date:4/25/2009

cause serious liver disease, leading to cirrhosis, primary liver cancer and even death. Patients infected with the genotype 1 hepatitis C virus account for approximately 75% of the chronic hepatitis C patients in the U.S.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. The filing of global marketing applications for Albuferon is planned in fall 2009. Two Phase 3 clinical trials of LymphoStat-B are ongoing, with results expected in July and November 2009.

In January 2009, HGS began delivery of 20,000 doses of ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax; completion of delivery is expected in the second quarter. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.

For more information about HGS, please visit the Company's web site at www.hgsi.com. To view the EASL oral presentation reporting results of the ACHIEVE 1 clinical t
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. First Human Study to Show Sun Chlorella A Supports Heart Health
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
8. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
9. Drug Development Program Started Based on CAP(R) Human Cell Line
10. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Today, iHealth Lab Inc. announced it ... Ltd. for its first institutional round of funding. The ... global reach, accelerate growth and innovation, and invest in ... investment, Xiaomi Ventures will join iHealth,s board of directors, ... and ecommerce. "We are very pleased to ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... Va., Sept. 20, 2011 Rock Creek Pharmaceuticals, a ... ), announced that on September 19, 2011 a utility ... Office ("PTO"). This utility patent application is based on ... various products containing anatabine and the administration of anatabine ...
... Sept. 20, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... to be held October 13-14, 2011 at Nomura,s Singapore ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 2Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 3Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 4
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare ... project’s social media efforts. StudioPMG is honored to be a ... of beauty as it applies to disabled women. , ... Baer and Vanessa Silberman, who wanted to create a photo ... Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen later joined ...
(Date:9/19/2014)... September 19, 2014 -- Recent two-generation approaches to ... are receiving increasing attention from researchers, advocates, and ... to enable them to move to jobs that ... early care and education for children, these programs ... However, according to a new report from ...
(Date:9/19/2014)... 2014 As summer vacations end and everyone ... NY now reminds area patients about the reality and impact ... population affected by gum disease, there is simply not an ... 20 years Dr. Krishnan has treated patients with varying degrees ... patients that come in due to common symptoms such as ...
(Date:9/19/2014)... Recently, Top10BestSEOHosting.com has compared many professional ... Web Hosting and Bluehost are the best VPS ... to most people, VPS (Virtual Private Server) is ... into many servers, each of which has the ... dedicated computer,” the manager of Top10BestSEOHosting.com says. ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... LA JOLLA, Calif., Jan. 29 There,s a rumble ... their feet and planting,their behinds on yoga mats and ... World Health Research shows that,74% of Americans have expressed ... A surge in popularity of Pilates, Yoga, Qigong, Meditation, ...
... recurrence and painful side effects, small trial finds , , ... to treating deep vein thrombosis, injecting the clot-busting drug ... the risk of complications and recurrence, a small U.S. ... of blood thinners appears to completely destroy the clots, ...
... Opportunities for the Company, -- Potentially Denotes a Positive Sign ... ... Process, NEW YORK and HAIKOU, China, ... Board: CPHI),which develops, manufactures, and markets generic and brand,bio-pharmaceutical products in ...
... Ind., Jan. 29 , ... Quarter Highlights, -- Net Sales of $1.07 billion represents an increase of 15% ... 15% reported (10% constant currency), -- Diluted EPS were ... period, and $1.18 adjusted, an increase of 16% over the prior year ...
... MS -- Cold and flu season is upon ... year, according to,the Centers for Disease Control. A cold ... in children and the elderly. Early detection,is key, especially ... days,of the infection,s onset., (Photo: http://www.newscom.com/cgi-bin/prnh/20080129/NYTUFNS1 ...
... for blood clots in the legs appears to be safe ... February issue of Radiology. The study found that injecting or ... deep vein thrombosis (DVT) and reduces the risk of subsequent ... clear blood clots rapidly and safely, restoring blood flow in ...
Cached Medicine News:Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 2Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 3Health News:Clot-Busting Drug Offers New Approach to DVT 2Health News:Clot-Busting Drug Offers New Approach to DVT 3Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 2Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 4Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 5Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 6Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 7Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 8Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 9Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 10Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 11Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 12Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 13Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 14Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 15Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 16Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 17Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2
Provides the security of braided polyester suture and ease of an automated knot for vascular closure of 5-8Fr....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: